Comparison between low and high doses of radioactive iodine in the treatment of thyroid cancer
Phase 2
- Conditions
- Diffrentiated Thyroid Cancer.Malignant neoplasm of thyroid gland
- Registration Number
- IRCT138706171100N2
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 341
Inclusion Criteria
Patients with differentiated thyroid carcinoma (DTC): without any history of ablation therapy; with no palpable mass in the neck; with no evidence of capsular; vascular or lymph node invasion. Exclusion criteria: Any area of I-131 uptake in post-treatment whole body scan; Failing to follow the patients.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment with I-131. Timepoint: 6 Months. Method of measurement: Tg, AntiTg tests and whole body scan with I-131.
- Secondary Outcome Measures
Name Time Method Disease recurrence. Timepoint: 6 and 12 months. Method of measurement: Lab measurements, sonography and clinical assessment.